Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines

PHASE3CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

November 22, 2021

Primary Completion Date

January 31, 2022

Study Completion Date

June 25, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

CoronaVac/CoronaVac

Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.

BIOLOGICAL

CoronaVac/BNT162b2

"First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.~Second dose of BNT162b2 at 21-day +/- 3 days. Each dose of the Pfizer-BioNTech COVID-19 Vaccine is 0.3 ml. Each prefilled syringe contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2"

Trial Locations (5)

1000

STEG head office (Governorate of Tunis), Tunis

1002

Institut Pasteur de Tunis, Tunis

2080

Vaccination center of Ariana, Aryanah

2094

Géant supermarket (Governorate of Ariana), Aryanah

7030

Leoni factory (Governorate of Bizerte), Bizerte

All Listed Sponsors
lead

Institut Pasteur de Tunis

OTHER

NCT05668065 - Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines | Biotech Hunter | Biotech Hunter